Key Highlights:
Apollo Hospitals and Siemens Healthineers collaborate to create AI-enabled imaging solutions for diagnosis and management of liver disease in India.
The initiative is directed towards the diagnosis of non-invasive MASLD for early identification and improved patient care through newer imaging and AI.
Key Background :
Liver disease is fast emerging as an Indian health problem today with metabolic dysfunction-associated steatotic liver disease (MASLD) being the limelight. MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), has a strong link with increasing obesity, diabetes, and physical inactivity. It has been estimated that 9% to 32% of Indians are likely to develop this disease but is found largely underdiagnosed because proper screening instruments are not available.
Apollo Hospitals and Siemens Healthineers signed a long-term research collaboration agreement for the establishment of AI-based solutions to facilitate early diagnosis, monitoring, and management of liver disease. Their contract was officially signed in March 2025 and recently reaffirmed by signing an addendum at Hyderabad in July 2025.
Area of cooperation is quantitative ultrasound imaging with AI for the liver diseases of fibrosis and steatosis in their initial development phases. The integration of AI into clinical practice will enable clinicians to keep a close eye on the disease process and arrive at more informed decisions.
Apollo Hospitals, a healthcare chain at the top of India, has huge clinical exposure as well as exposure to wide patient base. Siemens Healthineers, an international medical technology powerhouse, has experience in the latest imaging systems as well as AI-based diagnostics solutions. Together they partner in the mission of developing low-cost, replicable diagnostic models that could be deployed within the urban and rural healthcare delivery settings.
Dr. Sangita Reddy clarified that pre-diagnosis is the key to avoiding violent liver disease complications, and that the project provides a non-invasive, effective answer to diagnostics today. She made the key point that AI modeling would enable the enabling of strategic screening approaches and enhance long-term outcomes by allowing high-risk groups to be identified early.
Hariharan Subramanian went on to add that the partnership is not merely a matter of enhancing the quality of life. Closing diagnostic gaps and offering timely intervention, the initiative is committed to alleviating the health burden of liver disease for both patients and the healthcare system. It also aspires to transform the healthcare horizon through digital innovation and precision medicine.
This collaboration is an evolutionary move towards translational application of AI-powered solutions to routine clinical practice. This is a stepping stone towards the provision of more effective, prognostic, and cost-effective liver care to millions of Indians, particularly in low-resource settings.